# Brii Bio Presents Cross-Study Analysis of Post-Treatment HBsAg Rebound at APASL 2026

- Link: https://www.thailand-business-news.com/pr-news/brii-bio-presents-cross-study-analysis-of-post-treatment-hbsag-rebound-at-apasl-2026
- Published: 2026-04-26T18:00:00+07:00
- Author: PR Newswire

_– Participants achieving HBsAg loss with pegylated interferon alfa (PEG-IFNα) ±
elebsiran or BRII-179 demonstrated favorable off-treatment clinical outcomes, with
most HBsAg rebounds <10 IU/mL and HBV DNA rebound infrequent and not associated 
with clinically significant ALT elevation. These findings indicate durable post__‑
__treatment immunological control, supporting the potential for safe nucleos(t)ide
reverse transcriptase inhibitor (NRTI) discontinuation in regimens combining PEG-
IFNα with novel therapeutic modalities._

_– Shorter NRTI consolidation was not associated with higher HBsAg rebound rates,
suggesting that shortening or potentially eliminating the NRTI consolidation period
may be feasible in these combination regimens._

DURHAM, N.C. and BEIJING, April 26, 2026 /PRNewswire/ — [Brii Biosciences Limited](https://www.briibio.com/en/)("
Brii Bio," "Brii," or the "Company," stock code: 2137.HK), a biotechnology company
developing therapies to improve patient health and choice across diseases with high
unmet medical need, presented a cross-study analysis of post-treatment hepatitis
B surface antigen (HBsAg) rebound profiles at the 35^(th) Annual Meeting of Asian
Pacific Association for the Study of the Liver (APASL 2026), taking place from April
22-25, 2026 in Istanbul, Turkey.

This analysis evaluated post-end-of-treatment (EOT) HBsAg rebound in NRTI-experienced
participants with chronic hepatitis B virus (HBV) infection who achieved HBsAg loss
in the Phase 2 ENSURE study or the Phase 2 BRII-179-002 study. The Phase 2 ENSURE
study is designed to assess the safety and efficacy of combination approaches aimed
at improving functional cure outcomes. Cohorts 1-3 evaluate elebsiran in combination
with PEG-IFNα compared to PEG-IFNα monotherapy, while Cohort 4 evaluates the potential
role of BRII-179 in identifying immunologically responsive patients and improving
HBsAg loss rate. BRII-179-002 is a multicenter, randomized, double-blind, proof-
of-concept Phase 2 study that evaluates BRII-179 as an add-on therapy to PEG-IFNα.

Data from the two studies were pooled to assess the incidence, magnitude and clinical
relevance of HBsAg rebound following EOT in participants treated with PEG‑IFNα alone
or in combination with elebsiran or BRII‑179. Across studies, participants demonstrated
favorable off‑treatment clinical outcomes. All HBsAg rebounds remained below 100
IU/mL with most rebounds remaining below 10 IU/mL. HBV DNA rebound was infrequent
and not associated with clinically meaningful alanine aminotransferase (ALT) elevations
following NRTI discontinuation. Together, these results suggest durable post‑treatment
immunological control and further support the potential for safe discontinuation
of NRTIs in PEG‑IFNα-based combination with novel therapeutic modalities. Notably,
shorter NRTI consolidation periods (12 to 20 weeks versus 24 weeks) were not associated
with higher HBsAg rebound rates, suggesting that shortening—and potentially eliminating—
the NRTI consolidation period may be feasible in future treatment strategies.

"We are encouraged by the growing evidence showing that our novel therapeutic combinations
can achieve not only rapid HBsAg loss, but also durable immunological control after
treatment withdrawal," said David Margolis, M.D., Chief Medical Officer of Brii 
Bio. "These findings strengthen our confidence in the potential of BRII‑179 and 
elebsiran as components of next‑generation HBV cure strategies, and we look forward
to additional readouts from our ongoing studies throughout 2026."

Additional details of the oral presentation are as follows:

**Title:** Cross-study Analysis of HBsAg Rebound Following Treatments of Elebsiran/
BRII-179 in Combination with Peginterferon Alfa

**Session/Presentation Type:** Oral Presentation Session 58

**Date and time: **13:40 – 15:10 on April 25 (UTC+3)

**Presenter:** Jidong Jia, M.D., Ph.D., Professor of Medicine at the Liver Research
Centre, Beijing Friendship Hospital, Capital Medical University in Beijing, China

 ◦ Post‑EOT HBsAg rebound was observed in 24 of 55 participants (43.6%) with similar
   rates during NRTI consolidation (13/55, 23.6%) and after NRTI discontinuation(
   11/41, 26.8%).
 ◦ Shorter NRTI consolidation was not associated with higher HBsAg rebound rates
   after NRTI withdrawal, with 15.0% (3/20) of participants receiving 12–20 weeks
   of NRTI consolidation and 23.8% (5/21) of those receiving 24 weeks experiencing
   HBsAg rebound by 24 weeks after NRTI discontinuation.
 ◦ The magnitude of HBsAg rebound was limited, with all rebounds <100 IU/mL and 
   75.0% (18/24) remaining <10 IU/mL. HBV DNA rebound after NRTI discontinuation
   was infrequent, with >90% (38/41) of participants maintaining HBV DNA <LLOQ at
   the last available visit. No ALT flares were observed; one participant exceeded
   the normal range and received NRTI retreatment at investigator discretion.

**About Hepatitis B**

Hepatitis B virus (HBV) infection is one of the world’s most significant infectious
disease threats with more than 254 million people infected globally.^([)^(1]) Chronic
HBV infection is the leading cause of liver disease and an estimated 820,000 people
die of complications from chronic HBV infection each year.^([1]) HBV is of exceptional
concern in China, where 87 million people are chronically infected.^([2])

**About BRII-179**

BRII-179 is a novel recombinant protein-based HBV immunotherapeutic candidate that
expresses the Pre-S1, Pre-S2, and S HBV surface antigens, designed to induce enhanced
and broad B-cell and T-cell immunity. In November 2023, the Center for Drug Evaluation(
the "CDE") of China’s National Medical Products Administration (the "NMPA") granted
BRII-179 Breakthrough Therapy Designation.

**About** **Elebsiran**

Elebsiran is an investigational subcutaneously administered HBV-targeting siRNA 
designed to degrade HBV RNA transcripts and limit the production of hepatitis B 
surface antigen. It has the potential to have direct antiviral activity against 
HBV and HDV. It is the first siRNA in the clinic to include Enhanced Stabilization
Chemistry Plus technology to enhance stability and minimize off-target activity,
which potentially can result in an increased therapeutic index. Brii Bio licensed
exclusive rights to develop and commercialize elebsiran for the Greater China territory
from Vir Biotechnology, Inc. in 2020. In May 2024, the CDE of China’s NMPA granted
elebsiran Breakthrough Therapy Designation.

**About Brii Bio**

Brii Biosciences Limited ("Brii Bio", stock code: 2137.HK) is a biotechnology company
developing therapies to improve patients’ health by addressing high unmet medical
needs with limited treatment options. The Company is advancing a broad pipeline 
of unique therapeutic candidates with lead programs against hepatitis B virus (HBV)
infection. The Company is led by a visionary and experienced leadership team and
has operations in both China and the United States. For more information, visit 
[www.briibio.com](https://www.briibio.com/).

  |

^(1) World Health Organization. (April 2024). Global hepatitis report 2024: action for access in low- and middle-income countries. World Health Organization. Retrieved from [https://www.who.int/publications/i/item/9789240091672](https://www.who.int/publications/i/item/9789240091672)

^(2) World Health Organization. Hepatitis. World Health Organization. Retrieved from [https://www.who.int/china/health-topics/hepatitis#:~:text=There%20are%2087%20million%20people,living%20with%20chronic%20hepatitis%20C.](https://www.who.int/china/health-topics/hepatitis#:~:text=There%20are%2087%20million%20people,living%20with%20chronic%20hepatitis%20C.)

  |

---

  |  This article was produced by Cision PR Newswire, our trusted news partner. The views expressed and the content presented here are solely those of the author and may not fully reflect the opinions of Thailand Business News. |

---

 
**Read the original article :** [Brii Bio Presents Cross-Study Analysis of Post-Treatment HBsAg Rebound at APASL 2026 ](http://www.prnasia.com/story/archive/4942807_AE42807_0?rand=184833)
